Technical Analysis for TSHA - Taysha Gene Therapies, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | -0.80% | |
| MACD Bullish Centerline Cross | Bullish | -0.80% | |
| 180 Bullish Setup | Bullish Swing Setup | -0.80% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -0.80% | |
| Pocket Pivot | Bullish Swing Setup | -0.80% | |
| Wide Range Bar | Range Expansion | -0.80% | |
| BB Squeeze Ended | Range Expansion | -0.80% | |
| Outside Day | Range Expansion | -0.80% | |
| Above Upper BB | Strength | -0.80% | |
| Up 3 Days in a Row | Strength | -0.80% |
| Alert | Time |
|---|---|
| Down 3% | 7 minutes ago |
| Fell Below Upper Bollinger Band | 7 minutes ago |
| 60 Minute Opening Range Breakdown | 14 minutes ago |
| Expansion Pivot Buy Entry | about 3 hours ago |
| Bullish 180 Entry | about 3 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.89 |
| 52 Week Low | 0.5 |
| Average Volume | 2,546,140 |
| 200-Day Moving Average | 2.21 |
| 50-Day Moving Average | 2.61 |
| 20-Day Moving Average | 2.48 |
| 10-Day Moving Average | 2.56 |
| Average True Range | 0.28 |
| RSI (14) | 64.66 |
| ADX | 13.31 |
| +DI | 31.06 |
| -DI | 14.48 |
| Chandelier Exit (Long, 3 ATRs) | 2.31 |
| Chandelier Exit (Short, 3 ATRs) | 2.98 |
| Upper Bollinger Bands | 2.83 |
| Lower Bollinger Band | 2.13 |
| Percent B (%b) | 1.41 |
| BandWidth | 27.88 |
| MACD Line | 0.01 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0469 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.09 | ||||
| Resistance 3 (R3) | 3.99 | 3.57 | 3.92 | ||
| Resistance 2 (R2) | 3.57 | 3.32 | 3.62 | 3.87 | |
| Resistance 1 (R1) | 3.34 | 3.17 | 3.46 | 3.44 | 3.81 |
| Pivot Point | 2.92 | 2.92 | 2.98 | 2.97 | 2.92 |
| Support 1 (S1) | 2.69 | 2.67 | 2.81 | 2.79 | 2.41 |
| Support 2 (S2) | 2.27 | 2.52 | 2.32 | 2.35 | |
| Support 3 (S3) | 2.04 | 2.27 | 2.30 | ||
| Support 4 (S4) | 2.14 |
